Zdravljenje diseminiranega plazmocitoma na Klinicnem oddelku za hematologijo UKC Ljubljana z avtologno presaditvijo krvotvornih maticnih celic v letih 2014 in 2015

Introduction: In the period from 1 Jauary 2014 to 31 December 2015 at the Clinical Department of Hematology, University Medical Centre Ljubljana, we treated 73 multiple myeloma patients with rst autologous hematopoietic stem-cell transplantation (HSCT). Methods and results: Patients age ranged from 27 to 72 years with the median age of 60 years. Induction treatment at the time of diagnosis consisted of: VD (bortezomib, dexamethasone) 60/73 paients (82 %), VCD (bortezomib, cyclophosphamide, dexamethasone) 10/73 patients (14 %) and VTD (bortezomib, thalidomide, dexamethasone) 3/73 (5 %) patients. As part of induction therapy, patients received from 1 to 10 cycles of treatment. Response to induction therapy prior to HSC (hematopoietic stem cells) collection was as follows: CR (complete remission) 7/73 (10 %), VGPR (very good partial response) 28/73 (38 %), PR (partial response) 23/73 (32 %), SD (stable disease) 11/73 (15 %) and PD (progressive disease) 4/73 (5 %) patients. Response to induction therapy immediately prior to autologous HSCT: CR9/73 (12 %), VGPR 32/73 (44 %), PR 17/73 (23 %), SD 8/73 (11 %) and PD 6/73 (8 %) patients. Response to induction therapy and the rst autologous HSCT at D+100 aer HSCT: CR 9/67 (13 %), VGPR 34/67 (51 %), PR 12/67 (18 %), SD 3/67 (4 %) and PD 7/67 (10 %) patients (in 6 patients data are missing, because they have not been mature yet at the time of this report). Sixty-three patients were treated with single HSCT , while 10 patients received double or second HSCT. The overall mortality of patients treated during the period from 1 January 2014 to 31December 2015 was 6/73 or 8.2 %. Conclusions: The treatment of multiple myeloma with autologous HSCT remains the cornerstone of efficiency, as demonstrated by the increasing share of the most desired responses to treatment, ie. CR and VGPR. The treatment mortality rate was within expectation limits.